A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties

Journal of Medicinal Chemistry

Volumn 49, Issue 13, 2006, Pages 3753-3756

  Dyck, Brian ^a   Markison, Stacy ^a   Zhao, Liren ^a   Tamiya, Junko ^a   Grey, Jonathan ^a   Rowbottom, Martin W ^a   Zhang, Mingzhu ^a   Vickers, Troy ^a   Sorensen, Katie ^a   Norton, Christi ^a   Wen, Jenny ^a   Heise, Christopher E ^a   Saunders, John ^a   Conlon, Paul ^a   Madan, Ajay ^a   Schwarz, David ^a   Goodfellow, Val S ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; BENZOPYRIDAZINONE DERIVATIVE; HORMONE RECEPTOR; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; PYRIDAZINONE DERIVATIVE; RECEPTOR BLOCKING AGENT; THIENOPYRIDAZINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFECT; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEEDING BEHAVIOR; HUMAN; NONHUMAN; OBESITY; RAT; RECEPTOR AFFINITY; WEIGHT REDUCTION;

ANIMALS; APPETITE DEPRESSANTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; BRAIN; EATING; HALF-LIFE; MALE; OBESITY; PERMEABILITY; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 33745666463     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051263c     Document Type: Article

References (36)

1. The World Health Report 2002. Reducing Risks, Promoting Healthy Life; World Health Organization: Geneva, 2002.
2. Sanofi-Aventis Press Release. Rimonabant accepted for filing by the FDA. Sanofi-Aventis, Paris, June 23, 2005.
3. Qu, D.; Ludwig, D. S.; Gammeltoft, S.; Piper, M.; Pelleymounter, M. A.; Cullen, M. J.; Mathes, W. F.; Przypek, J.; Kanarek, R.; Maratos-Flier, E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996, 380, 243-247.
4. Della-Zuana, O.; Presse, F.; Ortola, C.; Duhault, J.; Nahon, J. L.; Levens, N. Acute and chronic administration of melanin-concentrating hormone enhances food intake and body weight in Wistar and Sprague-Dawley rats. Int. J. Obes. 2002, 26, 289-1295.
5. Shimada, M.; Tritos, N. A.; Lowell, B. B.; Flier, J. S.; Maratos-Flier, E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998, 396, 670-674.
6. (a) Marsh, D. J.; Weingarth, D. T.; Novi, D. E.; Chen, H. Y.; Trumbauer, M. E.; Chen, A. S.; Guan, X.-M.; Jiang, M. M.; Feng, Y.; Camacho, R. E.; Shen, Z.; Easter, F. G.; Yu, H.; Metzger, J. M.; Kuca, S. J.; Shearman, L. P.; Gopal-Truter, S.; MacNeil, D. J.; Strack, A. M.; MacIntyre, D. E.; Van der Ploeg, L. H. T.; Qian, S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3240-3245.
7. (b) Chen, Y.; Hu, C.; Hsu, C.-K.; Zhang, Q.; Bi, C.; Asnicar, M.; Hsiung, H. M.; Fox, N.; Slieker, L. J.; Yang, D. D.; Heiman, M. L.; Shi, Y. Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 2002, 143, 2469-2477.
8. (a) Borowsky, B.; Durkin, M. M.; Ogozalek, K.; Marzabadi, M. R.; DeLeon, J.; Lagu, B.; Heurich, R.; Lichtblau, H.; Shaposhnik, Z.; Daniewska, I.; Blackburn, T. P.; Branchek, T. A.; Gerald, C.; Vaysse, P. J.; Forray, C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. 2002, 8, 825-830.
9. (b) Takekawa, S.; Asami, A.; Ishihara, Y.; Terauchi, J.; Kato, K.; Shimomura, Y.; Mori, M.; Murakoshi, H.; Kato, K.; Suzuki, N.; Nishimura, O.; Fujino, M. T-226296: A novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur. J. Pharmacol. 2002, 438, 129-135.
10. (c) McBriar, M. D.; Guzik, H.; Xu, R.; Paruchova, J.; Li, S.; Palani, A.; Clader, J. W.; Greenlee, W. J.; Hawes, B. E.; Kowalksi, T. J.; O'Neill, K.; Spar, B.; Weig, B. Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics. J. Med. Chem. 2005, 48, 2274-2277.
11. (d) Palani, A.; Shapiro, S.; McBriar, M. D.; Clader, J. W.; Greenlee, W. J.; Spar, B.; Kowalski, T. J.; Farley, C.; Cook, J.; van Heek, M.; Weig, B.; O'Neill, K.; Graziano, M.; Hawes, B. Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity. J. Med. Chem. 2005, 48, 4746-4749.
12. (e) Souers, A. J.; Gao, J.; Wodka, D.; Judd, A. S.; Mulhern, M. M.; Napier, J. J.; Brune, M. E.; Bush, E. N.; Brodjian, S.; Dayton, B. D.; Shapiro, R.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym P. R. Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 2005, 15, 2752-2757.
13. (f) Souers, A. J.; Gao, J.; Brune, M.; Bush, E.; Wodka, D.; Vasudevan, A.; Judd, A. S.; Mulhern, M.; Brodjian, S.; Dayton, B.; Shapiro, R.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym, P. R. Identification of 2-(4-benzyloxyphenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity. J. Med. Chem. 2005, 48, 1318-1321.
14. (g) Vasudevan, A.; Verzal, M. K.; Wodka, D.; Souers, A. J.; Blackburn, C.; Che, J. L.; Lai, S.; Brodjian, S.; Falls, D. H.; Dayton, B. D.; Govek, E.; Daniel, T.; Geddes, B.; Marsh, K. C.; Hernandez, L. E.; Collins, C. A.; Kym, P. R. Identification of aminopiperidine benzamides as MCHr1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 3412-3416.
15. (h) Huang, C. Q.; Baker, T.; Schwarz, D.; Fan, J.; Heise, C. E.; Zhang, M.; Goodfellow, V. S.; Markison, S.; Gogas, K. R.; Chen, T.; Wang, X.-C.; Zhu, Y.-F. 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)- pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 3701-3706.
16. (i) Kym, P. R.; Iyengar, R.; Souers, A. J.; Lynch, J. K.; Judd, A. S.; Gao, J.; et al. Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. 2005, 48, 5888-5891.
17. (j) Vasudevan, A.; LaMarche, M. J.; Blackburn, C.; Che, J. L.; Luchaco-Cullis, C. A.; Lai, S.; et al. Identifiation of ortho-amino benzamides and nicotinamides as MCHr1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 4174-4179.
18. (k) McBriar, M. D.; Guzik, H.; Shapiro, S.; Paruchova, J.; Xu, R.; Palani, A.; Clader, J. W.; Cox, K.; Greenlee, W. J.; Hawes, B. E.; Kowalski, T. J.; O'Neill, K.; Spar, B. D.; Weig, B.; Wetson, D. J.; Farley, C.; Cook, J. Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicycle[3.2.1]hexyl ureas. J. Med. Chem. 2006, 49, 2294-2310.
19. (l) Kowalski, T. J.; Spar, B. D.; Weig, B.; Farley, C.; Cook, J.; Ghibaudi, L.; Fried, S.; O'Neill, K.; Del Vecchio, R. A.; McBriar, M.; Guzik, H.; Clader, J.; Hawes, B. E.; Hwa, J. Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice. Eur. J. Pharmacol. 2006, 535, 182-191.
20. (m) Kym, P. R.; Souers, A. J.; Campbell, T. J.; Lynch, J. K.; Judd, A. S.; Iyengar, R.; et al. Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. 2006, 49, 2339-2352.
21. Rajachandran, L.; Beretta, E.; Doller, D.; Brodbeck, R. M.; Kinrade, M. B.; Cheng, C. S.; Fung, L. K.; Shaw, K. R.; Shaw, K. R.; Cassella, J. V.; Krause, J. E. Efficacy of a Novel MCHR1 Antagonist in Preventing Weight Gain in Dog. Presented at the North American Association for the Study of Obesity, Las Vegas, NV, November 14-18, 2004.
22. (a) Amgen, 2005. Available on line at www.amgen.com/science/pipe_AMG076. html.
23. (b) GlaxoSmithKline, 2005. Available on line at www.gsk.com/financial/ product_pipe-line.html.
24. Chaki, S.; Funakoshi, T.; Hirota-Okuno, S.; Nishiguchi, M.; Shimazaki, T.; Iijima, M.; Grottick, A. J.; Kanuma, K.; Omodera, K.; Sekiguchi, Y.; Okuyama, S.; Tran, T.-A.; Semple, G.; Thomsen, W. Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J. Pharmacol. Exp. Ther. 2005, 313, 831-839.
25. (a) Chaki, S.; Yamaguchi, J.; Yamada, H.; Kanuma, K.; Sekiguchi, Y. Melanin-concentrating hormone receptor 1 antagonists for the treatment of depression and anxiety. Drug Dev. Res. 2005, 65, 278-290.
26. (b) Dyck, B. Small molecule melanin-concentrating hormone receptor 1 antagonists as anxiolytic and antidepressive agents. Drug Dev. Res. 2005, 65, 291-300.
27. Ulven, T.; Frimurer, T. M.; Receveur, J.-M.; Little, P. B.; Rist, O.; Norregaard, P. K.; Hogberg, T. 6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode. J. Med. Chem. 2005, 48, 5684-5697.
28. Cherkez, S.; Herzig, J.; Yellin, H. Synthesis, saludiuretic, and antihypertensive activity of 6,7-disubstituted 1(2H)- and 3,4-dihydro-1(2H)- phthalazinones. j. Med. Chem. 1986, 29, 947-959.
29. Bryant, R. D.; Kunng, F.-A.; South, M. S. A large scale preparation of 3-chloro-5-methoxypyridazine. J. Heterocycl. Chem. 1995, 32, 1473-1476.
30. Ma, C.; Cho, S.; Falck, J. R.; Shin, D. Synthetic studies on isoquinoline derivatives with multidrug resistance (MDR) modulating activity. Heterocycles 2004, 63, 75-85.
31. R'kyek, O.; Maes, B. U. W.; Lemiere, G. L. F.; Dommisse, R. A. 5-Alkynyl-4-chloro- and 4-alkynyl-5-chloropyridazin-3(2H)-ones: convenient precursors for the preparation of 2-substituted pyrrolo[2,3-d]pyridazinones. Heterocycles 2003, 60, 2471-2483.
32. R'kyek, O.; Maes, B. U. W.; Lemiere, G. L. F.; Dommisse, R. A. 5-Alkynyl-4-chloro- and 4-alkynyl-5-chloropyridazin-3(2H)-ones towards oxygen and sulfur nucleophiles. Heterocycles 2002, 57, 2115-2128.
33. Klapars, A.; Antilla, J. C.; Huang, X.; Buchwald, S. L. A general and efficient copper catalyst for the amidations of aryl halides and the N-arylation of nitrogen heterocycles. J. Am. Chem. Soc. 2001, 123, 7727-7729.
34. Obach, R. S. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propanolol. Drug Metab. Dispos. 1997, 25, 1359-1369.
35. Yamada, M.; Miyakawa, T.; Duttaroy, A.; Yamanaka, A.; Moriguchi, T.; Makita, R.; Ogawa, M.; Chou, C. J.; Xia, B.; Crawley, J. N.; Felder, C. C.; Deng, C.-X.; Wess, J. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001, 410, 207-212.
36. Haab, F.; Stewart, L.; Dwyer, P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. 2004, 45, 420-429.